Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Raltegravir (RAL) is a novel and potent human immunodeficiency virus type 1 integrase inhibitor that is predominantly metabolized via glucuronidation. The protease inhibitor combination tipranavir (TPV) at 500 mg and ritonavir (RTV) at 200 mg (TPV-RTV) has inhibitory and inductive effects on metabol...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hanley, William D., Wenning, Larissa A., Moreau, Allison, Kost, James T., Mangin, Eric, Shamp, Trisha, Stone, Julie A., Gottesdiener, Keith M., Wagner, John A., Iwamoto, Marian
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology (ASM) 2009
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2704640/
https://ncbi.nlm.nih.gov/pubmed/19398643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01486-08
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak